An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 52212-2)

Pharmacology Biochemistry and Behavior

Volumn 86, Issue 3, 2007, Pages 499-504

  Rawls, Scott M ^a   Gomez, Teresa ^a   Raffa, Robert B ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid; Dependence; Glutamate; LY 235959; NMDA; Planaria; WIN 55212 2; Withdrawal

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR AGONIST; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; GLUTAMIC ACID; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG WITHDRAWAL; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TURBELLARIA;

ANIMALS; BENZOXAZINES; CANNABINOIDS; ISOQUINOLINES; MARIJUANA ABUSE; MORPHOLINES; MOTOR ACTIVITY; NAPHTHALENES; PLANARIANS; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANCE WITHDRAWAL SYNDROME;

MAMMALIA; PLANARIA; TURBELLARIA;

EID: 33947528392     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.01.010     Document Type: Article

References (56)

1. Aceto M.D., Scates S.M., Lowe J.A., and Martin B.R. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282 (1995) R1-R2
2. Aceto M.D., Scates S.M., Lowe J.A., and Martin B.R. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278 (1996) 1290-1295
3. Aceto M.D., Scates S.M., and Martin B.B. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 416 (2001) 75-81
4. Adams M.L., Kalicki J.M., Meyer E.R., and Cicero T.J. Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester. Life Sci 52 (1993) PL245-PL249
5. Agata K. The Zoological Society Prize. Molecular and cellular approaches to planarian regeneration. Zoolog Sci 19 (2002) 1391-1392
6. Agata K., and Watanabe K. Molecular and cellular aspects of planarian regeneration. Semin Cell Dev Biol 10 (1999) 377-383
7. Algeri S., Carolei A., Ferretti P., Gallone C., Palladini G., and Venturini G. Effects of dopaminergic agents on monoamine levels and motor behavior in planaria. Comp Biochem Physiol C 74 (1983) 27-29
8. Arnold W.P., Mittal C.K., Katsuki S., and Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A 74 (1977) 3203-3207
9. Beardsley P.M., and Martin B.R. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal. Eur J Pharmacol 387 (2000) 47-53
10. Buttarelli F.R., Pontieri F.E., Margotta V., and Palladini G. Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism. Prog Neuro-Psychopharmacol Biol Psych 26 (2002) 65-68
11. Cappendijk S.L., Duval S.Y., de Vries R., and Dzoljic M.R. Comparative study of normotensive and hypertensive nitric oxide synthase inhibitors on morphine withdrawal syndrome in rats. Neurosci Lett 183 (1995) 67-70
12. Carolei A., Margotta V., and Palladini G. Proposal of a new model with dopaminergic-cholinergic interactions for neuropharmacological investigations. Neuropsychobiology 1 (1975) 355-364
13. Cebria F., Kudome T., Nakazawa M., Mineta K., Ikeo K., Gojobori T., et al. The expression of neural-specific genes reveals the structural and molecular complexity of the planarian central nervous system. Mech Dev 116 (2002) 199-204
14. Crowley T.J., Macdonald M.J., Whitmore E.A., and Mikulich S.K. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 50 (1998) 27-37
15. Diana M., Melis M., Muntoni A.L., and Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A 95 (1998) 10269-10273
16. Fidecka S., and Langwinski R. Interaction between ketamine and ethanol in rats and mice. Pol J Pharmacol Pharm 41 (1989) 23-32
17. Garthwaite J. Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 14 (1991) 60-67
18. Garthwaite J., Garthwaite G., Palmer R.M., and Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 172 (1989) 413-416
19. Gonzalez S., Cebeira M., and Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav 81 (2005) 300-318
20. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol 125 (1998) 1567-1577
21. Justinova Z., Goldberg S.R., Heishman S.J., and Tanda G. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav 81 (2005) 285-299
22. Kimes A.S., Vaupel D.B., and London E.D. Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. Psychopharmacology (Berl) 112 (1993) 521-524
23. Kouri E.M., Pope Jr. H.G., and Lukas S.E. Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology (Berl) 143 (1999) 302-308
24. Koyuncuoglu H., Gungor M., Sagduyu H., and Aricioglu F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol Biochem Behav 35 (1990) 829-832
25. Lichtman A.H., and Martin B.R. Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 42 (2002) 20S-27S
26. MacDermott A.B., Mayer M.L., Westbrook G.L., Smith S.J., and Barker J.L. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321 (1986) 519-522
27. McCaslin P.P., and Morgan W.W. 2-Amino-7-phosphonoheptanoic acid, a selective antagonist of N-methyl-D-aspartate, prevents barbital withdrawal-induced convulsions and the elevation of cerebellar cyclic GMP in dependent rats. Neuropharmacology 26 (1987) 731-735
28. Morrisett R.A., Rezvani A.H., Overstreet D., Janowsky D.S., Wilson W.A., and Swartzwelder H.S. MK-801 potently inhibits alcohol withdrawal seizures in rats. Eur J Pharmacol 176 (1990) 103-105
29. Newmark P.A., and Sanchez Alvarado A. Not your father's planarian: a classic model enters the era of functional genomics. Nat Rev Genet 3 (2002) 210-219
30. Newmark P.A., Reddien P.W., Cebria F., and Sanchez Alvarado A. Ingestion of bacterially expressed double-stranded RNA inhibits gene expression in planarians. Proc Natl Acad Sci U S A 100 (2003) 11861-11865
31. Palladini G., Ruggeri S., Stocchi F., De Pandis M.F., Venturini G., and Margotta V. A pharmacological study of cocaine activity in planaria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 115 (1996) 41-45
32. Passarelli F., Merante A., Pontieri F.E., Margotta V., Venturini G., and Palladini G. Opioid-dopamine interaction in planaria: a behavioral study. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 124 (1999) 51-55
33. Perkonigg A., Lieb R., Hofler M., Schuster P., Sonntag H., and Wittchen H.U. Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents. Addiction 94 (1999) 1663-1678
34. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74 (1997) 129-180
35. Pertwee R.G. Medical uses of cannabinoids: the way forward. Addiction 94 (1999) 317-320
36. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (2006) S163-S171
37. Rabbani M., Wright J., Butterworth A.R., Zhou Q., and Little H.J. Possible involvement of NMDA receptor-mediated transmission in barbiturate physical dependence. Br J Pharmacol 111 (1994) 89-96
38. Raffa R.B., and Desai P. Description and quantification of cocaine withdrawal signs in Planaria. Brain Res 1032 (2005) 200-202
39. Raffa R.B., and Martley A.F. Amphetamine-induced increase in planarian locomotor activity and block by UV light. Brain Res 1031 (2005) 138-140
40. Raffa R.B., and Valdez J.M. Cocaine withdrawal in Planaria. Eur J Pharmacol 26 430 (2001) 143-145
41. Raffa R.B., Valdez J.M., Holland L.J., and Schulingkamp R.J. Energy-dependent UV light-induced disruption of (-)sulpiride antagonism of dopamine. Eur J Pharmacol 20 406 (2000) R11-R12
42. Raffa R.B., Holland L.J., and Schulingkamp R.J. Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. J Pharmacol Toxicol Methods 45 (2001) 223-226
43. Raffa R.B., Stagliano G.W., and Umeda S. kappa-Opioid withdrawal in Planaria. Neurosci Lett 349 (2003) 139-142
44. Rasmussen K., Fuller R.W., Stockton M.E., Perry K.W., Swinford R.M., and Ornstein P.L. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 197 (1991) 9-16
45. Rawls S.M., Gomez T., Stagliano G.W., and Raffa R.B. Measurement of glutamate and aspartate in Planaria. J Pharmacol Toxicol Methods 53 (2006) 291-295
46. Rawls S.M., Rodriguez T., Baron D.A., and Raffa R.B. A nitric oxide synthase inhibitor (l-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res 1099 (2006) 82-87
47. Rubino T., Patrini G., Massi P., Fuzio D., Vigano D., Giagnoni G., et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 285 (1998) 813-819
48. Sarnat H.B., and Netsky M.G. The brain of the planarian as the ancestor of the human brain. Can J Neurol Sci 12 (1985) 296-302
49. Steppuhn K.G., and Turski L. Diazepam dependence prevented by glutamate antagonists. Proc Natl Acad Sci U S A 90 (1993) 6889-6893
50. Tanganelli S., Antonelli T., Morari M., Bianchi C., and Beani L. Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci Lett 122 (1991) 270-272
51. Tokuyama S., Wakabayashi H., and Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur J Pharmacol 295 (1996) 123-129
52. Tsou K., Patrick S.L., and Walker J.M. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280 (1995) R13-R15
53. Tzavara E.T., Valjent E., Firmo C., Mas M., Beslot F., Defer N., et al. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. Eur J Neurosci 12 (2000) 1038-1046
54. Umeda S., Stagliano G.W., and Raffa R.B. Cocaine and kappa-opioid withdrawal in Planaria blocked by D-, but not L-, glucose. Brain Res 1018 (2004) 181-185
55. Umeda S., Stagliano G.W., Borenstein M.R., and Raffa R.B. A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in Planaria. J Pharmacol Toxicol Methods 51 (2005) 73-76
56. Venturini G., Stocchi F., Margotta V., Ruggieri S., Bravi D., Bellantuono P., et al. A pharmacological study of dopaminergic receptors in planaria. Neuropharmacology 28 (1989) 1377-1382